November 15th, 2019
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.
Should I buy Novartis stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Novartis stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Novartis stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 5 ratings published for NVS stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-29||Jefferies Financial Group||n/a||Buy|
|2019-7-5||JPMorgan Chase & Co.||n/a||Sell|
|2019-7-23||Kepler Capital Markets||Buy||Hold|
|2019-4-10||Morgan Stanley||Equal Weight||Underweight|
Novartis stock analysis
Novartis ended yesterday at $90.04 and appreciated a tiny 0.59%.
Novartis shares appreciated 0.59% to $90.04 yesterday. Since price and SMA100d lines crossed up on Tuesday, NVS climbed $1.41 (1.59%). On July, NVS hit new all time highs, pushing higher previous ATH of $93.65 recorded on June. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Novartis shares stepped up 1.89% this week, ending at $90.04. With this, it's been 5 green weeks in a row, gaining $3.44 or 4.00%.
Far behind is the all-time high Novartis hit by mid July but price is just -5.22% below that top. Since this week when NVS stock price broke up the SMA20w line, it gained $1.67 (1.89%).
Novartis stock price history
Novartis IPO was on November 7th, 1996 at $13.47 per share1. Since then, NVS stock surged a 568.40%, with an average of 24.70% per year. If you had invested $1,000 in Novartis stock in 1996, it would worth $5,684.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Novartis stock historical price chart
NVS stock reached all-time highs on July with a price of $95.00.
Novartis stock price target is $105.00Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' NVS stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we only found 1 price prediction for Novartis stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareNovartis disappointed experts on January when it published an Earnings per Share (EPS) of $1.24 when the analysts' forecast was $1.33.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Novartis annual revenues jumped an excellent 6.05% to $53,166.00 M USD from $50,135.00 marked in 2017. However, its profit margin (compared to revenues) soared to 23.72%, that is $12,611.00 million.
|2013||$48,290 M||-||$8,520 M17.6%||-|
|2014||$53,634 M||11.07%||$10,210 M19.0%||19.84%|
|2015||$50,387 M||-6.05%||$17,783 M35.3%||74.17%|
|2016||$49,436 M||-1.89%||$6,712 M13.6%||-62.26%|
|2017||$50,135 M||1.41%||$7,703 M15.4%||14.76%|
|2018||$53,166 M||6.05%||$12,611 M23.7%||63.72%|
Quarterly financial resultsNovartis reported $13,664.00 M in revenues for 2018-Q4, a 4.14% up compared to previous quarter. Reported quarter earnings marked $1,195.00 M with a profit margin of 8.75%. Profit margin depreciated a -3.62% compared to previous quarter when profit margin was 12.37%. When comparing sales to same quarter last year, Novartis sales marked a decent growth and gained a 3.80%.
|2017-Q2||$12,050 M||-||$1,950 M16.2%||-|
|2017-Q3||$11,950 M||-0.83%||$2,000 M16.7%||2.56%|
|2017-Q4||$13,164 M||10.16%||$1,976 M15.0%||-1.20%|
|2018-Q1||$12,929 M||-1.79%||$2,025 M15.7%||2.48%|
|2018-Q2||$13,452 M||4.05%||$7,768 M57.7%||283.60%|
|2018-Q3||$13,121 M||-2.46%||$1,623 M12.4%||-79.11%|
|2018-Q4||$13,664 M||4.14%||$1,195 M8.7%||-26.37%|
|2019-Q1||$11,455 M||-16.17%||$1,766 M15.4%||47.78%|
Novartis ownershipWhen you are planning to invest in a stock, it's always worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Novartis, 0.00% of all outstanding shares are owned by its staff.
In case of Novartis stock, 11.69% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVS stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Novartis:
|Market cap||$206.2 B||$151.7 B||$95.5 B||$109.8 B||$354.9 B|
|Total shares||2,290.0 M||1,770.0 M||1,630.0 M||2,490.0 M||2,630.0 M|
|Float shares||2,130.0 M||1,760.0 M||1,630.0 M||2,450.0 M||2,630.0 M|
|- Institutional holdings (%)||11.7%||76.5%||75.0%||11.0%||69.2%|
|- Insider holdings (%)||0.0%||0.7%||0.1%||0.0%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$89.37 - $90.22|
|Average true range||$0.94|
|50d mov avg||$87.17|
|100d mov avg||$88.91|
|200d mov avg||$85.89|
Novartis performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Novartis against , Bristol-Myers Squibb, GlaxoSmithKline, , Merck, Pfizer, and Teva Pharmaceutical Industries in the following table:
Novartis competitorsOne check before trading any stock is to review a list of its competitors, in this case for Novartis. We selected 8 companies as Novartis competitors as they are in the same industry or have similar market objectives.
- Bristol-Myers Squibb (BMY)
- GlaxoSmithKline (GSK)
- Merck (MRK)
- Pfizer (PFE)
- Teva Pharmaceutical Industries (TEVA)
Latest Novartis stock news
- Seeking AlphaNovartis' Accelerated Review Sets Up A Potential Catalyst For FDA ApprovalJuly 25, 2019
- Seeking AlphaNovartis: A Transformation Story Not To Miss In 2019June 28, 2019
- Seeking AlphaNovartis Makes Substantial Pipeline Progress On A Couple Of FrontsJune 13, 2019
- Seeking AlphaNovartis Kisqali Might Have A Path Forward To Take On Pfizer's IbranceJune 11, 2019
- Seeking AlphaNovartis And Axovant Might Jointly Be Holding The Most Promising Neurodegeneration Drug In DevelopmentJune 4, 2019